Literature DB >> 15789901

Prolonged efficacy of infliximab for refractory adult-onset Still's disease.

M S Dilhuydy, R Vatan, G Etienne, M Longy-Boursier, P Mercié.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15789901

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN： 0392-856X            Impact factor:   4.473


× No keyword cloud information.
  4 in total

Review 1.  Diagnosis and management of adult onset Still's disease.

Authors:  P Efthimiou; P K Paik; L Bielory
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

2.  Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients.

Authors:  Paolo Sfriso; Roberta Priori; Guido Valesini; Silvia Rossi; Carlo Maurizio Montecucco; Anna D'Ascanio; Linda Carli; Stefano Bombardieri; Gaetana LaSelva; Florenzo Iannone; Giovanni Lapadula; Stefano Alivernini; Gianfranco Ferraccioli; Michele Colaci; Clodoveo Ferri; Daniela Iacono; Gabriele Valentini; Luisa Costa; Raffaele Scarpa; Andrea LoMonaco; Valentina Bagnari; Marcello Govoni; Ilaria Piazza; Silvano Adami; Francesco Ciccia; Giovanni Triolo; Elisa Alessandri; Maurizio Cutolo; Luca Cantarini; Mauro Galeazzi; Piero Ruscitti; Roberto Giacomelli; Francesco Caso; Paola Galozzi; Leonardo Punzi
Journal:  Clin Rheumatol       Date:  2016-05-20       Impact factor: 2.980

Review 3.  Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances.

Authors:  Apostolos Kontzias; Petros Efthimiou
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  Is anti-TNF switching in refractory Still's disease safe and effective?

Authors:  Nadia Emi Aikawa; Ana Cristina de Medeiros Ribeiro; Carla Gonçalves Schain Saad; Rosa Maria Rodrigues Pereira; Mauricio Levy; Clovis A Silva; Eloísa Bonfá; Jozélio Freire de Carvalho
Journal:  Clin Rheumatol       Date:  2011-04-05       Impact factor: 3.650
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.